Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 23% Improvement Relative Risk Hospitalization, 100mg TID 77% Hospitalization, 100mg BID 25% Hospitalization, 50mg BID -8% Fluvoxamine for COVID-19  Deng et al.  META ANALYSIS c19early.org Favors fluvoxamine Favors control

Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis

Deng et al., Reviews in Medical Virology, doi:10.1002/rmv.2501
Dec 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
27th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00011 from 20 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
Systematic review and meta-analysis of 9 RCTs (N=5,861) evaluating fluvoxamine for the outpatient treatment of COVID-19, showing lower hospitalization with treatment, with improved results for higher doses. 100mg BID/TID showed lower hospitalization, while 50mg BID did not.
6 meta analyses show significant improvements with fluvoxamine for mortality Deng, hospitalization Deng, Deng (B), Lee, Lu, Marcec, and severity Nakhaee.
Currently there are 20 fluvoxamine for COVID-19 studies, showing 43% lower mortality [12‑62%], 18% lower ventilation [-32‑50%], 10% higher ICU admission [-72‑326%], 26% lower hospitalization [4‑42%], and 27% fewer cases [18‑35%].
risk of hospitalization, 23.0% lower, RR 0.77, p = 0.03.
risk of hospitalization, 77.0% lower, RR 0.23, p = 0.17, 100mg TID.
risk of hospitalization, 25.0% lower, RR 0.75, p = 0.03, 100mg BID.
risk of hospitalization, 8.0% higher, RR 1.08, p = 0.86, 50mg BID.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Deng et al., 26 Dec 2023, peer-reviewed, 11 authors. Contact: dengj35@mcmaster.ca.
This PaperFluvoxamineAll
Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis
Jiawen Deng, Myron Moskalyk, Qi Kang Zuo, Cristian Garcia, Umaima Abbas, Harikrishnaa Ba Ramaraju, Daniel Rayner, Ye‐jean Park, Kiyan Heybati, Fangwen Zhou, Simran Lohit
Reviews in Medical Virology, doi:10.1002/rmv.2501
This systematic review and meta-analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of fluvoxamine for the outpatient management of COVID-19. We conducted this review in accordance with the PRISMA 2020 guidelines. Literature searches were conducted in MED-LINE, EMBASE, International Pharmaceutical Abstracts, CINAHL, Web of Science, and CENTRAL up to 14 September 2023. Outcomes included incidence of hospitalisation, healthcare utilization (emergency room visits and/or hospitalisation), mortality, supplemental oxygen and mechanical ventilation requirements, serious adverse events (SAEs) and non-adherence. Fluvoxamine 100 mg twice a day was associated with reductions in the risk of hospitalisation (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.58-0.97; I 2 = 0%) and reductions in the risk of healthcare utilization (RR 0.68, 95% CI 0.53-0.86; I 2 = 0%). While no increased SAEs were observed, fluvoxamine 100 mg twice a day was associated with higher treatment non-adherence compared to placebo (RR 1.61, 95% CI 1.22-2.14; I 2 = 53%). In subgroup analyses, fluvoxamine reduced healthcare utilization in outpatients with BMI ≥30 kg/m 2 , but not in those with lower BMIs. While fluvoxamine offers potential benefits in reducing healthcare utilization, its efficacy may be most pronounced in high-risk patient populations. The observed non-adherence rates highlight the need for better patient education and counselling. Future investigations should reassess trial endpoints to include outcomes relating to post-COVID sequelaes. Registration: This review was prospectively registered on PROSPERO (CRD42023463829).
| Study limitations The major limitation of this study is the potential presence of smallstudy effects for the outcome of hospitalisation and the requirement Note: GRADE Working Group quality of evidence rating. 28 High quality: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. Very low quality: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. Abbreviations: CI, Confidence Interval; RR, Risk Ratio. a The absolute risk in the intervention group (and its 95% confidence interval) is based on the baseline risk in the control group and the relative effect of the intervention (and its 95% CI). The baseline risk in the control group is calculated using GRADEpro GDT, by dividing the total control group sample size by the total incidence in the control group. This is different from the methods used for NNT calculations, which is the average control risk in the included studies for each outcome. b Downgraded by one level due to limitations in study design or execution (risk of bias); one of the included studies..
References
Anderson, Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability, J Affect Disord, doi:10.1016/s0165-0327(99)00092-0
Bhimraj, Gallagher, Lack of benefit of fluvoxamine for COVID-19 [internet, JAMA, doi:10.1001/jama.2022.23954
Boldrini, Canoll, Klein, How COVID-19 affects the brain, JAMA Psychiatry, doi:10.1001/jamapsychiatry.2021.0500
Bramante, Huling, Tignanelli, Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19, N Engl J Med [Internet, doi:10.1056/NEJMoa2201662
Bull, Hunkeler, Lee, Discontinuing or switching selective serotonin-reuptake inhibitors, Ann Pharmacother, doi:10.1345/aph.1A254
Cook, Sackett, The number needed to treat: a clinically useful measure of treatment effect, BMJ [Internet, doi:10.1136/bmj.310.6977.452
Deng, Heybati, Ramaraju, Zhou, Rayner et al., Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis, Infection [Internet, doi:10.1007/s15010-022-01825-8
Deng, None
Deng, Rayner, Ramaraju, Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2023.01.010
Dessie, Zewotir, Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients, BMC Infect Dis, doi:10.1186/s12879-021-06536-3
Flaherty, A simple method for evaluating the clinical literature, Fam Pract Manag
Greenblatt, Gupta, Kao, Drug repurposing during the COVID-19 pandemic: lessons for expediting drug development and access, Health Aff [Internet, doi:10.1377/hlthaff.2022.01083
Guyatt, Oxman, Montori, GRADE guidelines: 5. Rating the quality of evidence--publication bias, J Clin Epidemiol, doi:10.1016/j.jclinepi.2011.01.011
Guyatt, Oxman, Santesso, GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes, J Clin Epidemiol, doi:10.1016/j.jclinepi.2012.01.012
Guyatt, Oxman, Vist, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ [Internet, doi:10.1136/bmj.39489.470347
Harbord, Egger, Sterne, A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints, Stat Med [Internet, doi:10.1002/sim.2380
Hashimoto, Overview of the potential use of fluvoxamine for COVID-19 and long COVID, Discov Ment Health, doi:10.1007/s44192-023-00036-3
Higgins, Thomas, Chandler, Cochrane Handbook for Systematic Reviews of Interventions
Ibrahim, Shehta, Treatment with fluvoxamine in nonhospitalized coronavirus disease 2019 patients, J Chest Dis Tuberc, doi:10.4103/ecdt.ecdt_38_22
Irons, Fluvoxamine in the treatment of anxiety disorders, Neuropsychiatr Dis Treat
Keyloun, Hansen, Hepp, Gillard, Thase et al., Adherence and persistence across antidepressant therapeutic Classes: a retrospective Claims analysis among insured US patients with major depressive disorder (MDD), CNS Drugs, doi:10.1007/s40263-017-0417-0
Lee, Murthy, Corpo, Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2022.04.018
Lenze, Mattar, Zorumski, Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA [Internet, doi:10.1001/jama.2020.22760
Mccarthy, Naggie, Boulware, Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, JAMA [Internet, doi:10.1001/jama.2022.24100
Naggie, Effect of higher-dose fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial, medRxiv, doi:10.1101/2023.09.12.23295424
Page, Mckenzie, Bossuyt, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ [Internet, doi:10.1136/bmj.n71
Reiersen, Mattar, Ignacio, The STOP COVID 2 study: fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully remote randomized controlled trial, Open Forum Infect Dis, doi:10.1093/ofid/ofad419
Reis, Santos Moreira-Silva, Silva, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health [Internet, doi:10.1016/s2214-109x(21)00448-4
Reis, Silva, Silva, Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19, Ann Intern Med [Internet, doi:10.7326/m22-3305
Sansone, Sansone, Antidepressant adherence: are patients taking their medications?, Innov Clin Neurosci
Schwarzer, Carpenter, Rucker, Meta-Analysis with R [Internet, doi:10.1007/978-3-319-21416-0
Seo, Kim, Bae, Fluvoxamine treatment of patients with symptomatic COVID-19 in a Community treatment Center: a preliminary result of randomized controlled trial, Infect Chemother [Internet, doi:10.3947/ic.2021.0142
Siripongboonsitti, Ungtrakul, Tawinprai, Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe among mild to moderate COVID-19 patients: open-label randomized controlled trial (EFFaCo study), Int J Infect Dis [Internet, doi:10.1016/j.ijid.2023.06.018
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: a review of its mechanism of action and its role in COVID-19, Front Pharmacol, doi:10.3389/fphar.2021.652688
Sweeting, Sutton, Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Stat Med [Internet, doi:10.1002/sim.1761
Tan, Liu, Zhou, Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China, Immunology, doi:10.1111/imm.13223
Terrin, Schmid, Lau, In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias, J Clin Epidemiol, doi:10.1016/j.jclinepi.2005.01.006
Wang, Liu, Zhang, Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review, J Med Virol, doi:10.1002/jmv.28118
Wolff, Nee, Hickey, Marschollek, Risk factors for Covid-19 severity and fatality: a structured literature review, Infection [Internet, doi:10.1007/s15010-020-01509-1
Zeng, Brignardello-Petersen, Hultcrantz, GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach, J Clin Epidemiol [Internet, doi:10.1016/j.jclinepi.2022.07.014
Zhou, Deng, Heybati, Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis, Future Virol, doi:10.2217/fvl-2021-0244
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit